PMID- 10069682
OWN - NLM
STAT- MEDLINE
DCOM- 19990503
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 33
IP  - 3
DP  - 1999 Mar
TI  - Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene 
      expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
PG  - 451-60
AB  - Angiotensin-converting enzyme (ACE) inhibitors have proven an effective means to 
      control hypertension and manage cardiac hypertrophy. It is presently unknown if 
      newer specific angiotensin II subtype 1 receptor (AT1R) antagonists are as 
      effective or more effective in treating these conditions compared with ACE 
      inhibitors. There is evidence that these classes of drugs may affect cardiac 
      hypertrophy by different mechanisms. This study compared the effect of 
      irbesartan, an AT1R antagonist, with that of captopril, an ACE inhibitor, on 
      expression of early genetic markers of cardiac hypertrophy in lean male 
      SHHF/Mcc-fa(cp) rats. SHHF/Mcc-fa(cp) rats (n = 10/group) were given captopril 
      (100 mg/kg/day), irbesartan (50 mg/kg/day), or placebo for 16 weeks. Irbesartan 
      and captopril significantly reduced systolic pressure and produced similar 
      rightward shifts in the angiotensin I dose-response curve. Renal renin gene 
      expression was increased 8.6-fold by irbesartan and 17.7-fold by captopril. The 
      only effect on echocardiographic findings was a similar decrease in aortic peak 
      velocity, an index of systolic function, by both treatments. Early markers of 
      cardiac hypertrophy were significantly attenuated by both drugs. Both drugs 
      produced marked and equivalent reductions in left ventricular atrial natriuretic 
      peptide (ANP) messenger RNA (mRNA) levels compared with controls. This decrease 
      in ANP gene expression was accompanied by a decrease in plasma ANP concentration 
      in the treatment groups. The shift from V1 to V3 myosin isozymes was similarly 
      decreased in both treatment groups, compared with controls. These data suggest 
      that captopril and irbesartan are similarly effective in controlling expression 
      of genes associated with ventricular hypertrophy in heart failure-prone 
      SHHF/Mcc-fa(cp) rat.
FAU - Carraway, J W
AU  - Carraway JW
AD  - Department of Veterinary Biosciences, The Ohio State University, Columbus, USA.
FAU - Park, S
AU  - Park S
FAU - McCune, S A
AU  - McCune SA
FAU - Holycross, B J
AU  - Holycross BJ
FAU - Radin, M J
AU  - Radin MJ
LA  - eng
GR  - HL48835/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Isoenzymes)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptor, Angiotensin, Type 1)
RN  - 0 (Receptor, Angiotensin, Type 2)
RN  - 0 (Tetrazoles)
RN  - 11128-99-7 (Angiotensin II)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
RN  - 9041-90-1 (Angiotensin I)
RN  - 9G64RSX1XD (Captopril)
RN  - EC 3.4.23.15 (Renin)
RN  - EC 3.6.4.1 (Myosin Heavy Chains)
RN  - J0E2756Z7N (Irbesartan)
SB  - IM
MH  - Angiotensin I/pharmacology
MH  - Angiotensin II/pharmacology
MH  - Angiotensin Receptor Antagonists
MH  - Angiotensin-Converting Enzyme Inhibitors/pharmacology
MH  - Animals
MH  - Antihypertensive Agents/*pharmacology/therapeutic use
MH  - Atrial Natriuretic Factor/blood/drug effects/genetics
MH  - Biphenyl Compounds/*pharmacology/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Body Weight/drug effects
MH  - Captopril/*pharmacology/therapeutic use
MH  - Cardiomegaly/pathology/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Echocardiography/drug effects
MH  - Gene Expression/drug effects
MH  - Heart Failure/metabolism/physiopathology/*prevention & control
MH  - Irbesartan
MH  - Isoenzymes/drug effects
MH  - Male
MH  - Myosin Heavy Chains/drug effects
MH  - Organ Size/drug effects
MH  - RNA, Messenger/drug effects/metabolism
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Receptor, Angiotensin, Type 1
MH  - Receptor, Angiotensin, Type 2
MH  - Renin/genetics
MH  - Systole
MH  - Tetrazoles/*pharmacology/therapeutic use
EDAT- 1999/03/09 00:00
MHDA- 1999/03/09 00:01
CRDT- 1999/03/09 00:00
PHST- 1999/03/09 00:00 [pubmed]
PHST- 1999/03/09 00:01 [medline]
PHST- 1999/03/09 00:00 [entrez]
AID - 10.1097/00005344-199903000-00016 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1999 Mar;33(3):451-60. doi: 
      10.1097/00005344-199903000-00016.